tetano
Editor, Senior Moderator
Eur J Clin Pharmacol
. 2020 Jul 21.
doi: 10.1007/s00228-020-02963-4. Online ahead of print.
Inhibition of SARS-CoV-2 entry through the ACE2/TMPRSS2 pathway: a promising approach for uncovering early COVID-19 drug therapies
Georgia Ragia[SUP] 1 [/SUP], Vangelis G Manolopoulos[SUP] 2 3 [/SUP]
Affiliations
Abstract
Aim: The COVID-19 pandemic caused by infection with the novel coronavirus SARS-CoV-2 is urging the scientific community worldwide to intense efforts for identifying and developing effective drugs and pharmacologic strategies to treat the disease. Many of the drugs that are currently in (pre)clinical development are addressing late symptoms of the disease. This review focuses on potential pharmacologic intervention at an early stage of infection which could result in less-infected individuals and less cases with severe COVID-19 disease due to reduced virus entry into the cells.
Method: We scanned the literature for evidence on drugs that target the virus entry machinery into host cells and consist mainly of ACE2 and TMPRSS2, as well as other cellular molecules regulating ACE2 expression, such as ADAM-17 and calmodulin.
Results: Several drugs/drug classes have been identified. Most of them are already used clinically for other indications. They include recombinant soluble ACE2, indirect ACE2 modulators (angiotensin receptor blockers, calmodulin antagonists, selective oestrogen receptor modifiers), TMPRSS2 inhibitors (camostat mesylate, nafamostat mesylate, antiandrogens, inhaled corticosteroids) and ADAM-17 enhancers (5-fluorouracil).
Conclusion: Several agents have potential for prophylactic and therapeutic intervention at the early stages of SARS-CoV-2 infection and COVID-19 disease and they should be urgently investigated further in appropriate preclinical models and clinical studies.
Keywords: 5-fluorouracil; ACE2; ADAM-17; Angiotensin receptor blockers; Antiandrogens; COVID-19; Calmodulin antagonists; Camostat mesylate; Inhaled corticosteroids; Nafamostat mesylate; SARS-CoV-2; SERMs; TMPRSS2.
. 2020 Jul 21.
doi: 10.1007/s00228-020-02963-4. Online ahead of print.
Inhibition of SARS-CoV-2 entry through the ACE2/TMPRSS2 pathway: a promising approach for uncovering early COVID-19 drug therapies
Georgia Ragia[SUP] 1 [/SUP], Vangelis G Manolopoulos[SUP] 2 3 [/SUP]
Affiliations
- PMID: 32696234
- DOI: 10.1007/s00228-020-02963-4
Abstract
Aim: The COVID-19 pandemic caused by infection with the novel coronavirus SARS-CoV-2 is urging the scientific community worldwide to intense efforts for identifying and developing effective drugs and pharmacologic strategies to treat the disease. Many of the drugs that are currently in (pre)clinical development are addressing late symptoms of the disease. This review focuses on potential pharmacologic intervention at an early stage of infection which could result in less-infected individuals and less cases with severe COVID-19 disease due to reduced virus entry into the cells.
Method: We scanned the literature for evidence on drugs that target the virus entry machinery into host cells and consist mainly of ACE2 and TMPRSS2, as well as other cellular molecules regulating ACE2 expression, such as ADAM-17 and calmodulin.
Results: Several drugs/drug classes have been identified. Most of them are already used clinically for other indications. They include recombinant soluble ACE2, indirect ACE2 modulators (angiotensin receptor blockers, calmodulin antagonists, selective oestrogen receptor modifiers), TMPRSS2 inhibitors (camostat mesylate, nafamostat mesylate, antiandrogens, inhaled corticosteroids) and ADAM-17 enhancers (5-fluorouracil).
Conclusion: Several agents have potential for prophylactic and therapeutic intervention at the early stages of SARS-CoV-2 infection and COVID-19 disease and they should be urgently investigated further in appropriate preclinical models and clinical studies.
Keywords: 5-fluorouracil; ACE2; ADAM-17; Angiotensin receptor blockers; Antiandrogens; COVID-19; Calmodulin antagonists; Camostat mesylate; Inhaled corticosteroids; Nafamostat mesylate; SARS-CoV-2; SERMs; TMPRSS2.